Press Release

CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis(R) and Beovu(R) Oct 27, 2025 22:00 JST More info..

China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication
Sep 28, 2025 15:00 JST

China Medical System Holdings Limited ("CMS") is pleased to announce that its subsidiaries, Dermavon Holdings Limited ("Dermavon", an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by CMS on 22 April 2025 for details) together with its subsidiaries, obtained positive results from the phase 3 clinical trial (the "Trial") of ruxolitinib cream (the "Product") in patients with mild to moderate atopic dermatitis (AD) in China.
More info..

China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies
Sep 23, 2025 12:15 JST

China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the "Agreements") with Chongqing Genrix Biopharmaceutical Co., Ltd. ("Genrix Bio") for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, "Vecantoxatug") indicated for passive immunization against tetanus and Silevimig Injection (GR1801, "Silevimig") indicated for passive immunization following suspected rabies virus exposure, respectively.
More info..

CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
Aug 19, 2025 15:00 JST

On 18 August, China Medical System Holdings Limited ("CMS" or the "Company") announced its interim results for the six months ended 30 June 2025 (the "Reporting Period"), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation.
More info..

China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China
Jul 29, 2025 04:00 JST

China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) ("ZUNVEYL" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA).
More info..

CMS Collaborates with SGX to Explore New Paradigms for Industrial Globalization and Pharmaceutical Expansion Overseas across Emerging Markets
Jul 22, 2025 13:00 JST

On July 15 2025, to mark the successful secondary listing of China Medical System Holdings Limited ("CMS" or the "Group") on the Main Board of the Singapore Exchange ("SGX"), SGX and CMS co-hosted the "Singapore and Emerging Markets Pharmaceutical Industry Growth Forum & CMS SGX Secondary Listing Appreciation Dinner".
More info..

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia Apr 01, 2024 20:30 JST More info..

China Medical System Accredited by 'China's Top 100 Potential Enterprises' by Forbes China for Two Consecutive Years Mar 07, 2011 15:00 JST Compiled by Forbes China, the "China's Top 100 Potential Enterprises" list focuses on the SMEs in China, and is the first ranking of its kind to cover the SMEs across all industries. More info..

CMS Expects to Launch CMS024 for the Treatment of Primary Liver Carcinoma Three Years Ahead of Plan in 2013 Jan 28, 2011 12:00 JST China Medical Systems, its subsidiary and Kangzhe Pharmaceutical Research and Development (Shenzhen) Limited held a successful roundtable meeting with the State Food and Drug Administration ("SFDA") of China. More info..

China Medical System Holdings Issues FY2010 Earnings Guidance Jan 12, 2011 11:43 JST China Medical System Holdings Ltd. (HKSE:0867) expects to release its results for the year ended 31 December 2010 in early March 2011. More info..